增加全身照射剂量对重型血红蛋白病单倍体移植植入失败的影响:前瞻性临床试验
在约翰霍普金斯医院开展的前瞻性2期试验中,17例重型血红蛋白病患者接受全身照射400 cGy的单倍体骨髓移植,仅1例(6%)发生原发植入失败,13例(76%)达完全供者嵌合,无患者死亡。作者认为该策略可降低植入失败并维持安全性。
要点
- 17例重型血红蛋白病患者接受400 cGy全身照射的单倍体骨髓移植,原发植入失败1例(6%)。
- 13例(76%)达完全供者嵌合,3例(18%)为混合嵌合。
- 2-4级急性GVHD 5例(29%),慢性GVHD 3例(18%),随访期间均缓解。
核心结论
- 将全身照射增至400 cGy大幅降低了植入失败,同时维持了单倍体骨髓移植联合移植后环磷酰胺的安全性。
- 作者认为该治愈性手段不应再局限于HLA相合供者。
研究设计与样本
- 在约翰霍普金斯医院开展的前瞻性2期临床试验,计划主要终点为移植相关死亡和无进展生存,因试验于2017年停止入组而改为以嵌合状态评估植入。
- 纳入17例首次接受骨髓移植的2-70岁重型血红蛋白病患者,其中镰状细胞病12例(71%)、β地中海贫血重型5例(29%)。
- 预处理含兔源抗胸腺细胞球蛋白、氟达拉滨、环磷酰胺及第-1天单次400 cGy全身照射,第0天输注未经处理骨髓。
主要发现
- 17例中1例(6%)发生原发植入失败并恢复宿主造血。
- 17例中13例(76%)达完全供者嵌合,3例(18%)为混合供者-宿主嵌合。
- 17例中5例(29%)发生2-4级急性GVHD,其中4例(24%)最高为2级、1例(6%)为3级;3例(18%)发生慢性GVHD。
- 截至2019年8月4日全部患者存活,中位随访705天(范围355-1294,IQR 398-943)。
- 16例植入患者中仅1例(6%)仍依赖输血,14例(88%)停用免疫抑制。
关键数值与推荐
- 全身照射剂量为400 cGy,第-1天单次给予。
- 抗胸腺细胞球蛋白第-9天0.5 mg/kg、第-8和-7天2 mg/kg静脉给药。
- 氟达拉滨第-6至-2天30 mg/m2静脉给药;环磷酰胺第-6和-5天14.5 mg/kg静脉给药。
- GVHD预防:移植后第3和4天环磷酰胺50 mg/kg/天静脉给药,第5至35天吗替麦考酚酯15 mg/kg/次(最大1 g)每8小时口服,第5天起西罗莫司口服维持血药浓度5-15 ng/dL至少1年。
临床怎么用
- 作者认为,对于血红蛋白病,单倍体骨髓移植后的植入是可能的。
- 作者认为,既往报告的主要问题原发植入失败可能通过该策略得到解决。
- 作者认为,该治愈性手段不应再局限于HLA相合供者。
局限性
- 因美国医疗保险和医疗补助服务中心的覆盖决定要求设不移植对照臂,试验于2017年停止入组。
- 因无法进行原计划的统计分析,主要终点改为以嵌合状态评估植入。
- 本报告为试验停止入组后的主要分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although severe haemoglobinopathies can be cured with allogeneic blood or bone marrow transplantation, availability of matched donors and toxic effects can be problematic. We previously found that non-myeloablative haploidentical related bone marrow transplantation with post-transplantation cyclophosphamide expanded the donor pool while limiting graft-versus-host disease (GVHD). However, graft failure-albeit with full host haemopoietic recovery-occurred in 50% of patients. In this study, we investigated whether increasing total body irradiation from 200 cGy to 400 cGy would improve engraftment while maintaining the safety profile. METHODS: This study was done at Johns Hopkins Hospital (Baltimore, MD, USA). Patients aged 2-70 years receiving their first bone marrow transplant were eligible for inclusion in the study. Patients received rabbit-derived intravenous anti-thymocyte globulin 0·5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, intravenous fludarabine 30 mg/m2 on days -6 to -2, intravenous cyclophosphamide 14·5 mg/kg on days -6 and -5, and total body irradiation 400 cGy administered as a single fraction on day -1. We collected unmanipulated bone marrow and infused on day 0. GVHD prophylaxis comprised intravenous cyclophosphamide 50 mg/kg per day on days 3 and 4 after transplantation, oral mycophenolate mofetil 15 mg/kg per dose (maximum 1 g) every 8 h on days 5 to 35, and oral sirolimus to maintain a level of 5-15 ng/dL for at least 1 year starting on day 5. The original planned primary objectives of this phase 2 clinical trial were transplant-related mortality and progression-free survival. However, the coverage decision by the Centers for Medicare and Medicaid Services to only provide payment for allogeneic bone marrow transplantation for patients with sickle cell disease on a clinical trial that had a comparison arm with patients not receiving bone marrow transplantation prompted the closure of this trial to accrual in 2017. Therefore, as we were unable to perform our planned statistical analysis, the primary objective was modified to evaluate engraftment, assessed by chimerism. This trial is registered with ClinicalTrials.gov, number NCT00489281. The study is closed to new participants and this is the primary analysis. FINDINGS: Between Sept 24, 2014, and Aug 1, 2017, we enrolled 17 consecutive patients: 12 (71%) with sickle cell disease and 5 (29%) with β-thalassaemia major. The median patient age was 16 years (range 6-31, IQR 7·7-27·5). One (6%) of 17 patients had primary graft failure with recovery of host haemopoiesis. 13 (76%) of 17 patients achieved full donor chimerism and three (18%) had mixed donor-host chimerism. Five (29%) of 17 patients developed grade 2-4 acute GVHD, including four (24%) with maximal grade 2 GVHD and one (6%) with grade 3 GVHD. Chronic GVHD developed in three (18%) patients. As of their last follow-up visit, GVHD had resolved in all patients and no patients were receiving systemic GVHD therapy. All patients remained alive as of Aug 4, 2019, and the median follow-up duration was 705 days (range 355-1294; IQR 398-943). Only one (6%) of the 16 engrafted patients remained transfusion dependent, and 14 (88%) discontinued immunosuppression. INTERPRETATION: Increasing total body irradiation to 400 cGy substantially reduced graft failure while maintaining the safety of haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. These results suggest that engraftment after haploidentical bone marrow transplantation for haemoglobinopathies is possible, and primary graft failure-the main problem previously reported-might be addressed by this strategy. Therefore, this curative approach should no longer be restricted to patients with HLA-matched donors. FUNDING: Maryland Stem Cell Research Fund and US National Institutes of Health.
引用
- Bolaños-Meade J, Cooke KR, Gamper CJ, et al. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematol. 2019. PMID: 30878319. doi:10.1016/S2352-3026(19)30031-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。